Literature DB >> 11223672

Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancer.

S Aaltomaa1, P Lipponen, M Ala-Opas, V M Kosma.   

Abstract

BACKGROUND: The adhesion molecule CD44 standard (CD44s), and its variant isoforms v3 and v6 are associated with cell-to-cell adhesion. The down-regulation of CD44 standard and its variant isoform CD44v6 is linked with early cancer cell dissemination, but the relationship between CD44v3 and malignant features of prostate cancer (PC) has not been established previously.
METHODS: The expression of CD44s and its CD44v3 and CD44v6 isoforms was analysed by immunohistochemistry in 209 archival PC biopsy specimens to establish their prognostic value.
RESULTS: Down-regulation of CD44s and CD44v6 was related to high T classification, metastasis, high Gleason score, DNA aneuploidy, high S-phase fraction, high mitotic index, perineural growth and dense amount of tumour infiltrating lymphocytes (p < 0.03 for all). Down-regulation of CD44s and CD44v6 was related to poor survival in the entire cohort (p < 0.0001), in M0 tumours (p < 0.001) and in T1-2M0 tumours (p < 0.05). In needle biopsies and TURP specimens, the prognostic impact of the investigated parameters was similar. In the multivariate analysis, T classification (p = 0.0009), presence of metastases (p < 0.0001), Gleason score (p = 0.0060) and CD44v6 (p = 0.0220) expression were independent prognostic factors. In M0 tumours, T classification (p < 0.0001) and CD44v6 (p = 0.003) independently predicted survival.
CONCLUSION: Down-regulation of CD44s and its CD44v6 isoform is related to tumour malignancy and unfavourable prognosis in PC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11223672     DOI: 10.1159/000052428

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  18 in total

Review 1.  The androgen receptor and stem cell pathways in prostate and bladder cancers (review).

Authors:  Katarzyna Marcinkiewicz; Kymora B Scotland; Stephen A Boorjian; Emeli M Nilsson; Jenny Liao Persson; Per Anders Abrahamsson; Cinzia Allegrucci; Ieuan A Hughes; Lorraine J Gudas; Nigel P Mongan
Journal:  Int J Oncol       Date:  2011-09-28       Impact factor: 5.650

2.  Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells.

Authors:  Pongsanat Pongcharoen; Artit Jinawath; Rutaiwan Tohtong
Journal:  Clin Exp Metastasis       Date:  2011-08-11       Impact factor: 5.150

3.  CD44 expression in intraoral salivary ductal papillomas and oral papillary squamous cell carcinoma.

Authors:  Sarah G Fitzpatrick; Lindsay J Montague; Donald M Cohen; Indraneel Bhattacharyya
Journal:  Head Neck Pathol       Date:  2012-11-13

4.  Long-term recovery of irradiated prostate cancer increases cancer stem cells.

Authors:  Yong Mee Cho; Young Seok Kim; Mun Jung Kang; William L Farrar; Elaine M Hurt
Journal:  Prostate       Date:  2012-04-18       Impact factor: 4.104

5.  Investigation of FJ 194940.1 gene alternative splicing in colon cancer and its association with clinicopathological parameters.

Authors:  Malwina Bartczak-Tomczyk; Aleksandra Sałagacka; Marek Mirowski; Ewa Balcerczak
Journal:  Exp Ther Med       Date:  2011-11-09       Impact factor: 2.447

6.  Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface.

Authors:  B Desai; T Ma; J Zhu; M A Chellaiah
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429

7.  Effect of CD44 gene polymorphisms on risk of transitional cell carcinoma of the urinary bladder in Taiwan.

Authors:  Wei-Chun Weng; Yu-Hui Huang; Shun-Fa Yang; Shian-Shiang Wang; Wu-Hsien Kuo; Chao-Wen Hsueh; Ching-Hsuan Huang; Ying-Erh Chou
Journal:  Tumour Biol       Date:  2015-12-12

8.  CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.

Authors:  Lili Wang; Qin Liu; Dongliang Lin; Maode Lai
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  Prognostic significance of CD44s expression in resected non-small cell lung cancer.

Authors:  Yoon Ho Ko; Hye Sung Won; Eun Kyoung Jeon; Sook Hee Hong; Sang Young Roh; Young Seon Hong; Jae Ho Byun; Chan-Kwon Jung; Jin Hyoung Kang
Journal:  BMC Cancer       Date:  2011-08-07       Impact factor: 4.430

10.  Aberrant DNA methylation and prostate cancer.

Authors:  Sunipa Majumdar; Eric Buckles; John Estrada; Shahriar Koochekpour
Journal:  Curr Genomics       Date:  2011-11       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.